

DPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|                                     |                                   |
|-------------------------------------|-----------------------------------|
| Applicant: Jean-Claude Arnould      | 371 Filing Date: 09/29/2004       |
| Application No.: 10/509,633         | Attorney Docket No.: 100467-1P US |
| PCT Application No.: PCT/GB03/01405 | Examiner: Not yet assigned        |
| Title: Chemical Compounds           |                                   |

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 24<sup>th</sup> June 2005

Signature  
Lucy Padgett

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed before the mailing of the first Office Action on the merits.

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100467-1P US.

Respectfully submitted,



Name: Lucy Padget  
Dated: 24<sup>th</sup> June 2005  
Reg. No.: L0074  
Phone No.: 781-839-4182

Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 01760

Enclosures: Form SB08A  
Form SB08B  
Documents



Substitute for Form 1449/PTO

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 1 of 3

Application Number

10/509633

Filing Date

February 18, 2005

First Named Inventor

ARNOULD, Jean-Claude

Art Unit

Not yet assigned

Examiner Name

Not yet assigned

## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number                            | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|---|
|                    |                       | Number - Kind Code <sup>2</sup> (if known) |                                |  |   |
|                    | US1                   | US-4,533,672 A                             | 08-06-1985                     | Imperial Chemical Industries PLC                   |   |
|                    | US2                   | US-3,901,914                               | 08-26-1975                     | Merck & Co., Inc.                                  |   |
|                    | US3                   | US-4,952,584                               | 08-28-1990                     | Beecham Group p.l.c.                               |   |
|                    | US4                   | US-3,166,570                               | 01-19-1965                     | American Home Products Corporation                 |   |
|                    | US5                   | US-3,168,526                               | 02-02-1965                     | The Upjohn Company                                 |   |
|                    | US6                   | US-3,037,031                               | 05-29-1962                     | Warner-Lambert Pharmaceutical Company              |   |
|                    | US7                   | US-2,984,670                               | 05-16-1961                     | The Upjohn Company                                 |   |
|                    | US8                   | US-2,890,223                               | 06-09-1959                     | Research Company                                   |   |
|                    | US9                   | US-2,849,454                               | 08-26-1958                     | The Upjohn Company                                 |   |
|                    | US10                  | US-2,802,003                               | 08-06-1957                     | The Geschickter Fund for Medical Research, Inc.    |   |
|                    | US11                  | US-2,991,291                               | 07-04-1961                     | The Upjohn Company                                 |   |
|                    | US12                  | US-2,883,394                               | 04-21-1959                     | Geigy Chemical Corporation                         |   |
|                    | US13                  | US-2,789,984                               | 04-23-1957                     | The Upjohn Company                                 |   |
|                    | US14                  | US-5,424,329                               | 06-13-1995                     | Warner-Lambert Company                             |   |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup>           |
|--------------------|-----------------------|---|--------------------------------|--|--|--------------------------|
|                    |                       | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) |                                |  |  |                          |
|                    | AA                    | WO 01/92224 A1  | 12-06-2001                     | AstraZeneca AB                                     |  | <input type="checkbox"/> |
|                    | AB                    | WO 02/70478 A1  | 09-12-2002                     | AstraZeneca AB                                     |  | <input type="checkbox"/> |
|                    | AC                    | EP 1297833 A1   | 04-02-2003                     | Pfizer Products Inc.                               |  | <input type="checkbox"/> |
|                    | AD                    | CH 414639 +English Abstract   | 12-30-1966                     | Sandoz Ltd.  |  | <input type="checkbox"/> |
|                    | AE                    | WO 98/39323 A1  | 09-11-1998                     | Baylor University                                  |  | <input type="checkbox"/> |
|                    | AF                    | WO 99/29660 A1  | 06-17-1999                     | Astra Pharmaceuticals Ltd.                         |  | <input type="checkbox"/> |
|                    | AG                    | WO 99/29661 A1  | 06-17-1999                     | Astra Pharmaceuticals Ltd.                         |  | <input type="checkbox"/> |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 2 of 3

## Complete if Known

|                      |                      |
|----------------------|----------------------|
| Application Number   | 10/509633            |
| Filing Date          | February 18, 2005    |
| First Named Inventor | ARNOULD, Jean-Claude |
| Art Unit             | Not yet assigned     |
| Examiner Name        | Not yet assigned     |

## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number                            | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|--|
|                    |                       | Number - Kind Code <sup>2</sup> (if known) |                                |  |  |
|                    | US-                   |  |                                |  |  |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup>           |
|--------------------|-----------------------|---|--------------------------------|---|--|--------------------------|
|                    |                       | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) |                                |   |  |                          |
|                    | AH                    | WO 99/51598 A1  | 10-14-1999                     | Neurogen Corporation                                  |  | <input type="checkbox"/> |
|                    | AI                    | WO 99/51600 A1  | 10-14-1999                     | Neurogen Corporation                                  |  | <input type="checkbox"/> |
|                    | AJ                    | WO 00/48606 A1  | 08-24-2000                     | Oxigene, Inc.   |  | <input type="checkbox"/> |
|                    | AK                    | WO 00/66585 A1  | 11-09-2000                     | Neurogen Corporation                                  |  | <input type="checkbox"/> |
|                    | AL                    | WO 01/19794 A2  | 03-22-2001                     | Baylor UniversityS                                    |  | <input type="checkbox"/> |
|                    | AM                    | WO 01/29025 A2  | 04-26-2001                     | Merck & Co., Inc.                                     |  | <input type="checkbox"/> |
|                    | AN                    | WO 01/82909 A2  | 11-08-2001                     | Asta Medica AG  |  | <input type="checkbox"/> |
|                    | AO                    | EP 0372962 B1   | 07-20-1994                     | Beecham Pharmaceuticals                               |  | <input type="checkbox"/> |
|                    | AP                    | EP 0393575 B1   | 03-16-1994                     | G.D. Searle & Co.                                     |  | <input type="checkbox"/> |
|                    | AQ                    | JP 200080295 A2 +English Abstract   | 03-21-2000                     | Konica Co., Japan                                     |  | <input type="checkbox"/> |
|                    | AR                    | EP 0107963 B1   | 04-01-1987                     | Imperial Chemical Industries PLC                      |  | <input type="checkbox"/> |
|                    | AS                    | ES 227606 +English Abstract   | 03-01-1957                     | Drogas Vacunas y Sueros S.A.                          |  | <input type="checkbox"/> |
|                    | AT                    | GB 942548   | 11-27-1963                     | Sandoz Ltd.   |  | <input type="checkbox"/> |
|                    | AU                    | GB 873777   | 07-26-1961                     | The Upjohn Company                                    |  | <input type="checkbox"/> |
|                    | AV                    | GB 869775   | 06-07-1961                     | The Upjohn Company                                    |  | <input type="checkbox"/> |
|                    | AW                    | GB 834028   | 05-04-1960                     | The Upjohn Company                                    |  | <input type="checkbox"/> |
|                    | AX                    | GB 839628   | 06-29-1960                     | May & Baker Ltd.                                      |  | <input type="checkbox"/> |
|                    | AY                    | GB 770370   | 03-20-1957                     | Romeo Justoni & Raffaele Pessina                      |  | <input type="checkbox"/> |
|                    | AZ                    | CH 380129 +English Abstract   | 09-15-1964                     | Sandoz Ltd.   |  | <input type="checkbox"/> |

|                    |  |                 |
|--------------------|--|-----------------|
| Examiner Signature |  | Date Considered |
|--------------------|--|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 3 of 3

## Complete if Known

|                      |                      |
|----------------------|----------------------|
| Application Number   | 10/509633            |
| Filing Date          | February 18, 2005    |
| First Named Inventor | ARNOULD, Jean-Claude |
| Art Unit             | Not yet assigned     |
| Examiner Name        | Not yet assigned     |

Attorney Docket No. 100467-1 US

## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number                            | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|---|
|                    |                       | Number - Kind Code <sup>2</sup> (if known) |                                |  |   |
|                    | US-                   |  |                                |  |   |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document                       | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup>           |
|--------------------|-----------------------|---|--------------------------------|--|--|--------------------------|
|                    |                       | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) |                                |  |  |                          |
|                    | BA                    | FR 1388973 +English Abstract  | 02-12-1965                     | N. V. Philips' Gloeilampenfabrieken                                      |  | <input type="checkbox"/> |
|                    | BB                    | GB 1033253  | 06-22-1966                     | American Cyanamid Company  |  | <input type="checkbox"/> |
|                    | BC                    | GB 886684   | 01-10-1962                     | The Upjohn Company   |  | <input type="checkbox"/> |
|                    | BD                    | GB 841524   | 07-20-1960                     | May & Baker Ltd.   |  | <input type="checkbox"/> |
|                    | BE                    | FR 1238756 +English Abstract  | 02-12-1960                     | Laboratoires Francais de Chimiotherapie                                  |  | <input type="checkbox"/> |
|                    | BF                    | GB 832855   | 04-13-1960                     | Imperial Chemical Industries Ltd.  |  | <input type="checkbox"/> |
|                    | BG                    | GB 807620   | 01-21-1959                     | Imperial Chemical Industries Ltd.  |  | <input type="checkbox"/> |
|                    | BH                    | WO 94/14770 A1  | 07-07-1994                     | SmithKline Beecham PLC   |  | <input type="checkbox"/> |
|                    | BI                    | WO 99/12905 A1  | 03-18-1999                     | L'Oreal  |  | <input type="checkbox"/> |
|                    | BJ                    | EP 0708091 A1   | 04-24-1996                     | Sumitomo Pharmaceuticals Co., Ltd.                                       |  | <input type="checkbox"/> |
|                    | BK                    | SU 175967 +English Abstract   | 10-26-1965                     | Yakubovich, A. Ya.; Gitel, P. O.; Belyaeva, I. N.; Smolyanitskaya, V. V. |  | <input type="checkbox"/> |
|                    | BL                    | CH 402860 +English Abstract   | 05-31-1966                     | Sandoz Ltd.  |  | <input type="checkbox"/> |
|                    |                       |   |                                |  |  |                          |
|                    |                       |   |                                |  |  |                          |
|                    |                       |   |                                |  |  |                          |

|                    |  |                 |
|--------------------|--|-----------------|
| Examiner Signature |  | Date Considered |
|--------------------|--|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 1 of 5

## Complete if Known

|                      |                      |
|----------------------|----------------------|
| Application Number   | 10/509633            |
| Filing Date          | February 18, 2005    |
| First Named Inventor | ARNOULD, Jean-Claude |
| Art Unit             | Not yet assigned     |
| Examiner Name        | Not yet assigned     |

Attorney Docket No. 100467

## NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup>           |
|--------------------|-----------------------|---|--------------------------|
|                    | AA                    | SHEPPARD, G. S. '3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists' <i>Journal Of Medicinal Chemistry</i> vol. 37, no. 13, 2011-2032, 1994  | <input type="checkbox"/> |
|                    | AB                    | KWONG, F. Y & BUCHWALD, S. L. 'A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiols' <i>Org. Lett.</i> Vol. 4, no. 20, 3517-3520, 2002.  | <input type="checkbox"/> |
|                    | AC                    | DATABASE CROSSFIRE BEILSTEIN 'Beilstein institute zur foerderung der chemischen wissenschaften' Database Accession No. 8172403  | <input type="checkbox"/> |
|                    | AD                    | DATABASE CROSSFIRE BEILSTEIN 'Beilstein institute zur foerderung der chemischen wissenschaften' Database Accession No. 183150, reaction 2 of 4  | <input type="checkbox"/> |
|                    | AE                    | DATABASE CROSSFIRE BEILSTEIN 'Beilstein institute zur foerderung der chemischen wissenschaften' Database Accession No. 5433848  | <input type="checkbox"/> |
|                    | AF                    | MONGE A ET AL 'New indole and pyridazinoindole analogs – synthesis and study as inhibitors of phosphodiesterases and as inhibitors of blood platelet aggregation' <i>Archiv Der Pharmazie</i> vol. 328, no. 10, pp. 689-698, 1995.                              | <input type="checkbox"/> |
|                    | AG                    | ALEKSANDRZAK, K. McGOWN, A. T & HADFIELD, J. A. 'Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4' <i>Anti-Cancer Drugs</i> vol. 9, pp.545-550, 1998.  | <input type="checkbox"/> |
|                    | AH                    | McGOWN, A. T. & FOX, B. W. 'Structural and biochemical comparison of the anti-mitotic agents colchicines, combretastatin A4 and amphetamine' <i>Anti-Cancer Drug Design</i> vol. 3, pp. 249-254, 1989.  | <input type="checkbox"/> |
|                    | AI                    | GALBRAITH, S. M ET AL. 'Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo' <i>Anti-Cancer Research</i> vol. 21, pp. 93-102, 2001.                                   | <input type="checkbox"/> |
|                    | AJ                    | BOLTON, D ET AL 'Synthesis and potential anxiolytic activity of 4-amino-pyrido[2,3-b]indoles' <i>Bioorganic &amp; Medicinal Chemistry Letters</i> vol. 3, no. 10, pp. 1941-1946, 1993.  | <input type="checkbox"/> |
| Examiner Signature |                       | Date Considered   |                          |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 2 of 5

## Complete if Known

|                      |                      |
|----------------------|----------------------|
| Application Number   | 10/509633            |
| Filing Date          | February 18, 2005    |
| First Named Inventor | ARNOULD, Jean-Claude |
| Art Unit             | Not yet assigned     |
| Examiner Name        | Not yet assigned     |

Attorney Docket No. 100467-1 US

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup>           |
|--------------------|-----------------------|---|--------------------------|
|                    | AK                    | BLACKBURN, T, P. '11-amino-2,6-dimethyl-1,2,3,4-tetrahydro-6H-quinindolin-1-one, a novel GABA <sub>A</sub> modulator with Potential anxiolytic activity' <i>Bioorganic &amp; Medicinal Chemistry Letters</i> vol. 4, no. 2, pp. 279-284, 1994.                  | <input type="checkbox"/> |
|                    | AL                    | McGOWN, A, T ET AL 'Pre-clinical studies of a novel anti-mitotic agent, amphetinile' <i>Br J Cancer</i> vol. 57, pp. 157-159, 1988.   | <input type="checkbox"/> |
|                    | AM                    | McGOWN, A, T. & FOX, B, W. 'Interaction of the novel agent amphetinile with tubulin' <i>Br J Cancer</i> vol. 59, pp. 865-868, 1989.   | <input type="checkbox"/> |
|                    | AN                    | NEWELL, D, R ET AL 'Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics' <i>British Journal of Cancer</i> vol. 81(5), pp. 760-768, 1999.  | <input type="checkbox"/> |
|                    | AO                    | DARK, G, G. 'Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature' <i>Cancer Research</i> vol. 57, pp. 1829-1834, 1997.  | <input type="checkbox"/> |
|                    | AP                    | PLAYER, M, R & SOWELL, J, W. 'Synthesis of 1,3-disubstituted-2-amino-5-hydroxyindoles by reductive aromatization' <i>J Heterocyclic Chem</i> vol. 30 (125), pp. 125 - 128, 1993.  | <input type="checkbox"/> |
|                    | AQ                    | HESS, S ET AL. '7-deazaadenines bearing polar substituents: structure-activity relationships of new A <sub>1</sub> and A <sub>3</sub> adenosine receptor antagonists' <i>J Med Chem</i> vol. 43, pp. 4636-4646, 2000.   | <input type="checkbox"/> |
|                    | AR                    | FUSE, E ET AL 'Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity' <i>Journal of the National Cancer Institute</i> vol. 86, no. 13, 1994.   | <input type="checkbox"/> |
|                    | AS                    | EGER, K ET AL 'Synthesis of substituted indoles and pyrimido[4,5-b]indoles by dehydration of tetrahydroindoles and tetrahydropyrimidoindoles' <i>Liebigs Ann Chem</i> pp. 465-470, 1993.  | <input type="checkbox"/> |
|                    | AT                    | KEGLEVIC, D & GOLES, D 'Indole compounds. VI. Syntheses of indole thioethers by direct cyclization of phenylhydrazine hydrochlorides and aliphatic acetals under mild conditions' <i>Croatica Chemica Acta</i> vol. 42, pp. 513-521, 1970.                      | <input type="checkbox"/> |
|                    | AU                    | DESATY, D ET AL 'The synthesis of N-acetylserotonin' <i>Biochem Biophys Acta</i> vol. 62, pp. 179-180, 1962.  | <input type="checkbox"/> |
|                    | AV                    | MASHIMA, H & MATSUMURA, M. 'Roles of external ions in the excitation-contraction coupling of frog skeletal muscle' <i>Japan J Physiol</i> vol. 12, pp 639-653. 1962.  | <input type="checkbox"/> |
| Examiner Signature |                       | Date Considered   |                          |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 7/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 3 of 5

### Complete if Known

|                      |                      |
|----------------------|----------------------|
| Application Number   | 10/509633            |
| Filing Date          | February 18, 2005    |
| First Named Inventor | ARNOULD, Jean-Claude |
| Art Unit             | Not yet assigned     |
| Examiner Name        | Not yet assigned     |

Attorney Docket No. 100467-1 US

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | T <sup>2</sup>           |
|--------------------|-----------------------|--|--------------------------|
|                    | AW                    | HEATH-BROWN, B & PHILPOTT, P. G. 'Studies in the indole series. Part 1. Indolylalkylamines' <i>J Chem Soc</i> pp. 7165-7078, 1965.   | <input type="checkbox"/> |
|                    | AX                    | DESAI, H. K. & USGAONKAR, R. N. 'Isocoumarins. Part 1. Synthesis of 4-Methylisocoumarins' <i>Jour Indian Chem Soc</i> vol. 41, no. 12, pp. 821 – 829, 1964.  | <input type="checkbox"/> |
|                    | AY                    | HEACOCK, R. A. & HUTZINGER, O. 'The preparation of the hydroxyskatoles and 5,6-dihydroxyskatoles' <i>Canadian Journal of Chemistry</i> vol. 42, pp. 514 – 521, 1964.   | <input type="checkbox"/> |
|                    | AZ                    | MA, J. C, N & WARNHOFF, E. W. 'On the use of nuclear magnetic resonance for the detection, estimation and characterization of N-methyl groups' <i>Canadian Journal of Chemistry</i> vol. 43, pp. 1849 – 1869, 1965.  | <input type="checkbox"/> |
|                    | BA                    | BENIGNI, J. D & MINNIS, R. L. 'The synthesis of 5,6-dihydroxyindole and some of its derivatives (1)' <i>J Heterocyclic Chem</i> vol. 2, pp. 387 – 392, 1965.   | <input type="checkbox"/> |
|                    | BB                    | MARCHAND, B ET AL 'Preparative chemistry of indole compounds. 1. Preparation of phenylhydrazone of pyruvic acid esters from methyloxalacetic esters and diazonium salts and conversion of these compounds into indole-2-carboxylic esters' <i>J Prakt Chem</i> vol. 13, pp. 54-57, 1961. +English Abstract | <input type="checkbox"/> |
|                    | BC                    | TABORSKY, R. G. & DELVIGS, P. 'Synthesis of some substituted tryptophols of possible physiological importance and a study with 3-(2-acetoxyethyl)-5-methoxyindole (5-methoxytryptophol O-acetate) on sexual maturation' <i>J Med Chem</i> vol. 9, pp. 251 – 254, 1966.                                     | <input type="checkbox"/> |
|                    | BD                    | TABORSKY, R. G ET AL '6-hydroxyindoles and the metabolism of melatonin' <i>J Med Chem</i> vol. 8(6), pp 855-858, 1965.   | <input type="checkbox"/> |
|                    | BE                    | TABORSKY, R. G ET AL 'Synthesis and preliminary pharmacology of some 1-methylindoles' <i>J Med Chem</i> vol. 8(4), pp. 460 – 466, 1965.  | <input type="checkbox"/> |
|                    | BF                    | ARUTYUNYAN, G. S. ET AL 'Relations between chemical structure and pharmacological activity of 5-alkoxytryptamines' <i>Farmakol Toksikol</i> vol. 27(6), pp. 681 – 686, 1964. +English Abstract   | <input type="checkbox"/> |
| Examiner Signature |                       | Date Considered  |                          |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**Complete if Known****INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET 4 of 5

Application Number

10/509633

Filing Date

February 18, 2005

First Named Inventor

ARNOULD, Jean-Claude

Art Unit

Not yet assigned

Examiner Name

Not yet assigned

Attorney Docket No.

100467-1 US

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup>           |
|--------------------|-----------------------|---|--------------------------|
|                    | BG                    | KRASNYKH, P, G ET AL 'Radioprotective action of 5-methoxytryptamine and other alkoxytryptamines' <i>Radiobiologiya</i> vol. 2(1), pp. 156-160, 1962. +English Abstract  | <input type="checkbox"/> |
|                    | BH                    | SHAGALOV, N, P. ET AL 'Indole derivatives. XXI. Synthesis of 4- and 6-chloroindolylbutyric acids' <i>Zh Obshch Khim</i> vol. 34(5), pp. 1592 – 1595, 1964. +English Abstract  | <input type="checkbox"/> |
|                    | BI                    | KEGLEVIC, D ET AL 'The synthesis of 3,5-disubstituted indoles by cyclization under mild conditions' <i>Croat Chem Acta</i> vol. 33, pp. 83-88, 1961. +English Abstract  | <input type="checkbox"/> |
|                    | BJ                    | GREENBERG, A, J. & KETCHAM, R 'Determination of urinary indolic metabolites' <i>Journal of Pharmaceutical Sciences</i> vol. 67(4), pp. 478 – 480, 1978.   | <input type="checkbox"/> |
|                    | BK                    | COTTERILL ET AL 'Cyclopropamitoses, Novel Bioreductive Anticancer Agents. Synthesis, Electrochemistry, and Biological Activity of 7-Substituted Cyclopropamitoses and Related Indolequinones' <i>J Med Chem</i> vol.37(22), pp. 3834 – 3843, 1994               | <input type="checkbox"/> |
|                    | BL                    | COTTERILL ET AL 'Cyclopropamitoses, Novel Bioreductive Anticancer Agents. Synthesis, 7-Methoxycyclopropamitose and Related Indolequinones', <i>Tetrahedron</i> vol. 50(25), pp. 7657 – 7674, 1994.  | <input type="checkbox"/> |
|                    | BM                    | MOODY ET AL 'Synthesis and Biological Activity of Thiazolylindolequinones, Analogues of the Natural Product BE 10988', <i>J Med Chem</i> vol. 38(6), pp. 1039 – 1043, 1995.   | <input type="checkbox"/> |
|                    | BN                    | MOODY ET AL 'Synthesis and Cytotoxic of Thiazolyl Indolequinones', <i>Anti-Cancer Drugs</i> vol. 10, pp. 577 – 589, 1999.   | <input type="checkbox"/> |
|                    | BO                    | CHIKVAIDZE ET AL 'Soobshch Akad Nauk Gruz' Bulletin of the Academy of Sciences of Georgia, vol. 141(3), pp. 545-548, 1991. +English Abstract  | <input type="checkbox"/> |
|                    | BP                    | BESWICK ET AL 'The Synthesis of 4 – Substituted Indoles via Arenetricarbonylchromium(0) Complexes' <i>Tetrahedron</i> vol. 44(23), pp. 7325 – 7334, 1988.   | <input type="checkbox"/> |
|                    | BQ                    | NECHVATAL & WIDDOWSON 'A New Synthesis of 4-Substituted Indoles via Tricarbonylarenechromium(0) Complexes' <i>J Chem Soc Chem Commun</i> vol. 8, pp. 467-468, 1982.   | <input type="checkbox"/> |
|                    | BR                    | DICKENS ET AL 'Transition Metal Medicated Thiation of Aromatic Rings' <i>Tetrahedron</i> vol. 47(40), pp. 8621 – 8634, 1991.  | <input type="checkbox"/> |
|                    | BS                    | FUKUDA ET AL 'Directed C-7 Lithiation of 1-(2,2-Diethylbutanoyl)indoles' <i>Tetrahedron</i> vol. 55(30), pp. 9151 – 9162, 1999.   | <input type="checkbox"/> |
| Examiner Signature |                       | Date Considered   |                          |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 5 of 5

## Complete if Known

|                      |                      |
|----------------------|----------------------|
| Application Number   | 10/509633            |
| Filing Date          | February 18, 2005    |
| First Named Inventor | ARNOULD, Jean-Claude |
| Art Unit             | Not yet assigned     |
| Examiner Name        | Not yet assigned     |

Attorney Docket No. 100467-1 US

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup>           |
|--------------------|-----------------------|---|--------------------------|
|                    | BT                    | ALEXANDRZAK ET AL 'Antimitotic Activity of Diaryl Compounds with Structural Features Resembling Combretastatin A-4' <i>Anticancer Drugs</i> vol. 9(6), pp. 545-550, 1998.   | <input type="checkbox"/> |
|                    | BU                    | MCGOWAN & FOX 'Structural and Biochemical Comparison of the Anti-Mitotic Agents Colchicine, Combretastatin A4 and Amphethinile' <i>Anticancer Drug Des</i> vol. 3(4), pp. 249-254, 1989.  | <input type="checkbox"/> |
|                    | BV                    | MCGOWAN & FOX 'Interaction of the Novel Agent Amphetamine with Tubulin', <i>British Journal of Cancer</i> vol. 59(6), pp. 865 – 868, 1989.  | <input type="checkbox"/> |
|                    | BW                    | MCGOWAN & FOX 'Pre-Clinical Studies of a Novel Anti-Mitotic Agent, Amphetamine' <i>British Journal of Cancer</i> vol. 57(2), pp. 157 – 159, 1988.   | <input type="checkbox"/> |
|                    | BX                    | GAIRNS ET AL 'Synthesis of Fused 1 <sup>λ</sup> ,2-Thiazines(2-Azathiabenzenes)' <i>J Chem Soc Perkin Trans</i> vol. 1(3), pp. 483 – 489, 1986.   | <input type="checkbox"/> |
|                    | BY                    | ALLEN 'Synthesis of Indole-2-Carboxylic Acid Esters', <i>Synth Commun</i> vol. 29(3), pp. 447 – 455, 1999.  | <input type="checkbox"/> |
|                    | BZ                    | DUNAN & ANDRAKO 'Synthesis of 2-(N,N-Dialkylaminomethyl)-7-Phenylthioindoles', <i>J Pharm Sci</i> vol. 57(6), pp. 979 – 983, 1968.  | <input type="checkbox"/> |
|                    | CA                    | SOMEI & NATSUME 'Photochemical Rearrangements for the Synthesis of 3-,4- and 6-Substituted Indoles', <i>Tetrahedron Lett</i> vol. 27, pp. 2451 – 2454, 1973.  | <input type="checkbox"/> |
|                    | CB                    | MIRZIA SHVILY ET AL <i>Khim Geterotsiki Soedin</i> vol. 1, pp. 54 – 56, 1991. +English Abstract   | <input type="checkbox"/> |
|                    | CD                    | NERENBERG ET AL 'Radioimmunoassay of Oxfendazole in Bovine, Equine, or Canine Plasma or Serum', <i>J Pharm Sci</i> vol. 67(11), pp. 1553 – 1557, 1978.  | <input type="checkbox"/> |
|                    | CE                    | CHIKVAIDZE ET AL 'New Indole Derivatives: Synthesis and Antibacterial Activity' <i>Pharmaceutical Chemistry Journal</i> , Vol. 32, No. 1, pp.30-33, 1998  | <input type="checkbox"/> |
|                    | CF                    | MCCORMICK ET AL 'Characterization and Synthesis of a New Calcium Antagonist from the Venom of a Fishing Spider', <i>Tetrahedron Lett</i> vol. 49, No. 48, pp. 11155-11168, 1993   | <input type="checkbox"/> |
|                    | CG                    | CHIKVAIDZE ET AL 'Indole Derivatives 138.* Synthesis of Some New Sulfur-Containing Derivatives of Indole', <i>Chem Heterocycl Compa</i> , Vol. 27 No. 11 pp. 1218-1221, 1991  | <input type="checkbox"/> |
|                    |                       |   | <input type="checkbox"/> |

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.